Customised Services in Preclinical Inflammation

R&D activities

Redoxis founders and personel have a strong background in academic research on animal models of inflammation and autoimmunity with focus on redox regulation of the immune system.

Redoxis was founded as a R&D company with focus on development of small molecules targeting the NOX2 complex (phagocytic NADPH oxidase) for treatment of autoimmune conditions. That project is since May 2016 continued in our subsidiary ProNoxis. As a company we value connection with the academic research and engage in both research programmes and activities including exchange of personel between academic and industrial institutions. This connection and active works within the academic research field help us keep up to date with the recent findings and continue development of services provided. We are continuously increasing and refining the models we are providing, with the aim of being a reliable and cost efficient provider of preclinical models of autoimmunity and inflammation.

EU funded research projects

We value the connection to academic research and we aim to always expand and improve our knowledge and service portfolio. We are therefore happy to be part of several EU funded research programs. Our currently ongoing project are:


Alphavac project is a EuroStars funded program (E*115368) aimed at using engineered alphavirus vectors to develop a new antigen discovery and validation platform. The AlphaVac project will develop inducible animal models to screen for therapeutic targets for ALS (Amyotrophic Lateral Sclerosis) and other neurodegenerative diseases. The project involves Amarna Therapeutics (NL) and Redoxis (SE) with a total budget of 0.8 million Euro and a duration of 36 months with start date on September the 1st 2021.


COSMIC is a European Training Network funded from the European Union's Horizon 2020 research and innovation programme (grant agreement NO 765158). COSMIC (Combating disorders of adaptive immunity with systems medicine) is an international consortium coordinated byt he Academic Medical Center in Amsterdam and will deliver 14 next generation systems medicine professionals. COSMIC aims ot contribute to the European systems medicine infrastructure through collaboration with existing initiatives and by contributing to best practices that reduce time and cost to address clinical needs.


BUTTERFLY is a EuroStars funded program (E!12979) aimed to develop the first small molecule drug inhibitor of microRNAs for treatment of systemic lupus erythematous (SLE). Within this program, Saverna Therapeutics AG (CH), SpiroChem AG (CH) and Redoxis (SE) will strive to develop inhibitors or miR-155, targeting microRNAs. miR-155 is a master regulator of several inflammatory genes and are over expressed in SLE patients. The project has a total budget of 14 million Euro and a duration of 36 months with start date 1st of April 2019.


ACTION is a EuroStars funded program (E!114520) with aim to develop a ground-breaking therapy for autoimmune disease (AD). The novel drug will selectively target the recently discovered endocrine-immune interphase, with anticipated high efficacy rates and minimal side effects. The project is involving Kaass Discovery (N) and Redoxis (SE), has a total budget of 12 million Euro and a duration of 36 months with start date on 1st of October 2020.


NeutroCure (Development of "smart" amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation) H2020 funded programme ((H2020-FETOPEN-861878) aiming to take advantage of the immune regulatory effects of reactive oxygen species (ROS). Traditionally, ROS is considered harmful and mediating damage to cells and tissue as they are unstable molecules that easily react with other molecules. Many years of research however has highlighted the role of ROS in regulating inflammatory reseponses. In animal models, mice lacking ROS production are more susceptible to servera autoimmune diseases than wild type mice. Timing and concentration seem to be a major determinant for if ROS are damaging or immune regulating. NeutroCure is developing ways to control the spatial and temporal amplification of ROS generation to effectively treat pathologic conditions. The program has an overall budget of approximately 3 million Euro over 5 years with start in January 2020. The project is composed of research groups from University of Surrey (UK), Universitatsklinikum Erlangen (DE) Lvivskyi Nationalnyi Medychnyi Universitet Imeni Danyla Halytskoho (U), Centro Nacional de Investigaciones Cardiovasculares Carlos III (ES), Redoxis (SE) and Institut Gustave Roussy (F).